Variability and growth in spending for outpatient specialty pharmaceuticals.
暂无分享,去创建一个
C. Mullins | V. D. Hsu | A. DeVries | F. Palumbo | F. Meng
[1] J. Roski,et al. Anticipating the future: how the emergence of innovative biologic agents impacts benefit design, utilization, and provider relations. , 2015, Journal of managed care pharmacy : JMCP.
[2] M. Zitter. Defining the great debate. , 2004, The American journal of managed care.
[3] Paul C Nagle,et al. Defining and characterizing the late-stage biopharmaceutical pipeline. , 2003, The American journal of managed care.
[4] M. Edlin. Specialty pharmacies provide pipeline for low-volume, high-cost biotech drugs , 2003 .
[5] B. Hesselgrave. Helping to manage the high cost of rare diseases. , 2003, Managed care quarterly.
[6] D. Willcutts. Developing a management plan. , 2003, Managed care quarterly.
[7] D. Willcutts. Specialty pharmaceuticals: developing a management plan. , 2002, Managed care quarterly.